Ajan Reginald with Nobel Laureate Sir Martin Evans in Celixir (formerly known as Cell Therapy Ltd)
Sir Martin Evans, Nobel Laureate, and Ajan Reginald, former Global Head of Emerging Technologies at Roche, are two key names behind the foundation of Cell Therapy Ltd (CTL) in 2009. Eventually, going forward with a name up gradation; CTL got its new name as Celixir in the year 2016. Moreover, their dedicated team of world-class scientists and biotechnology specialists are duly involved in bringing breakthrough medicines and technology to simply change the way this medical world is operating.
On the other side, their team is working hard towards bringing cutting edge cell and gene therapies into picture, to further bring appropriate treatments and solutions for incurable and ill-treated health issues like heart failure and Cancer. The Company is also ensuring going by their hardcore work ethics and beliefs in each of their operational activities.
Values at Celixir Ltd.
Specialist – The Company always put their best efforts towards all those areas which demand specialized research for specific disease and health issues.
World Class – The firm has further tied up with some of the world leaders in science, medicine and business fields, whilst bringing their high end expertise into picture, with the innovation and research in regards to breakthrough in regenerative medicine.
Patient Champions – We always believe that understanding the needs and requirements of the patients around is quite important and our team of specialist has achieved the same with all the hard work and knowledge based expertise.
Virtuous – We, at Celixir got a history of achievements and breakthroughs in regenerative medicine and innovative solutions to support the health of millions of people around.
Access Driven – Our services are solely focused towards the betterment of millions of patients around the world and we are committed towards bringing the best of the regenerative medicine. This commitment is then backed by all our hardcore efforts and innovative thought process towards the same.
Exceptional – We always ensure providing the best motivation and support to all our employees which further makes them bring the best out of their efforts in all of our work processes.
Innovation is the beating heart of Celixir, a biotechnology company. In just 10 short years, the team of world class scientists and biotechnology leadership have worked to create over 20 tissue-specific regenerative medicines, all at various stages, some even undergoing testing currently – a feat unheard of in regenerative medicine.
Celixir is a leading world class biotechnology company invested in stem cell research and gene therapy, driven by in-house discoveries. With a focus on researching cell therapies and gene therapies, Celixir is investigating innovative ways to use stem cells in regenerative medicine.
Celixir was founded in 2009 by Nobel Laureate Professor Sir Martin Evans, who was awarded the Nobel Prize in Medicine for a series of pioneering discoveries about embryonic stem cells and DNA recombination in mammals – culturing and cultivating mice embryonic stem cells in a lab, and Ajan Reginald, a biotech entrepreneur and ex-Global Head of Emerging Technologies at Roche.
This unique technology platform is revolutionary in its field, leading the charge in the search for new ways to use stem cells to reshape patient healthcare, worldwide. Celixir develops cellular medicines to treat life threatening and life altering diseases. Their current focus is on CVS indications including heart failure and Myocardial infarction.
While Celixir is proud of their initial investigational cardiac regenerative medicine, Heartcel™, their business isn’t just heart disease. The team investigates all aspects of medicine that might benefit from stem cell therapy, exploring specialities such as oncology, diabetes, dermatology even orthopedics.
The future is looking incredibly rosy for regenerative medicine – the potential for success with stem cells is huge.
For More news Read Blog for: Ajan reginald celixir